Progenics Pharmaceuticals — Proxy Contest (October 2019)
56 slides from Progenics Pharmaceuticals's proxy contest presentation, Oct 30, 2019
Slide 1: Creating Shareholder Value Through the Advancement of Cancer Treatment
Progenics Creating Shareholder Value Through the Advancement of Cancer Treatment
Slide 2: Paving the Best Path Forward for Long-Term Shareholder Value
Paving the Best Path Forward for Long-Term Shareholder Value “a S . Progenics, ee ane
Slide 3: Safe Harbor Statements
Nee ll e TV @ Safe Harbor Statements e Important Information For Investors And Stockholders “This presentation doesnot constite an oer to zl or he zaltation of an offer o buy any secure or azalictaton of any vote or apprxainanyuedetoninvAicheuch offer, lettin asa woul be unl or toappropraereiraton o
Slide 4: Safe Harbor Statements (Cont'd)
Nee ll @ 6° Safe Harbor Statements (Cont’d) e Cautionary Statement Regarding Forward-Looking Statements “This presentation contaie projection ad other “Yorsardlcokng statements" regarding ature events, Statements contained in this communication tht refer to Progenic'etmsted or antipate fate ests or
Slide 5: Executive Summary
aa nnn ee. e Executive Summary e The Progenics Board heard the call for change at the Annual Meetingand has taken major steps to address shareholder feedback. V The Progenics Board has taken the necessary and prudent steps to secure Progenics’ future, including negotiatinga stock deal with Lantheus
Slide 6: Executive Summary
aa nnn @ «6° Executive Summary e v v Lantheus hasalready assembled a highly qualified leadership team -with radiopharmaceutical commercial, supply chain, manufacturing, clinical development, regulatory, financial and corporate governance expertise —a well-balanced leadership team that is ready andmo
Slide 7: A Lantheus-Progenics Combination Creates a Global Leader in Precision Diagnostics and Therapeutics
Diagnostics and Therapeutics 35% Ownership Stake PGNX equity holders own 35% of the combined entity, maintaining upside from Strong Pro Forma Financial Profile $370m in pro forma combined revenue generated through diversified & enhanced future clinical milestones revenue streams” $15 to $20m Operati
Slide 8: Complementary Core Capabilities Making a Global Leader
Complementary Core Capabilities Making a Global Leader A Global Leader in Progenics Lantheus Diagnostics and Oncology Medical Imaging: = Treatment SS Sere Rcbert cums bercpeut poral with commercialized DEFINI, global leading product in the ultrasound contrast ‘continuous product pipeline for further
Slide 9: Part I: The Board Has Taken Significant Steps to Secure Long-Term Shareholder Value
Part I: The Board Has Taken Significant Steps to Secure 9 Long-Term Shareholder Value Since the Last Annual an Meeting »~
Slide 10: In July, Shareholders Voted for Minority Change — PGNX Listened and Responded
In July, Shareholders Voted for Minority Change — PGNX Listened and « Responded with Immediate Action e 2019 AGM 1s —=—— A Today ¥ Change!n Board leadership with theresigations ofchalrman Peter Crowley andNom. ‘Committee chairman Michael kistoauch and the announcement of new Co-chais, Dr Karen PGNX
Slide 11: The Board Continues to Take Steps to Secure Progenics' Future
The Board Continues to Take Steps to Secure Progenics’ Future Based on Recent Shareholder Feedback PGNX Now Je PGNX and LNTH Together Strengthen Leadership and Governance Korn Ferry processtoldentity2 new Ditectrs, ncludinganew Chairperson '- Weleomed’2nominees from Velan'sconsentsolicitationslate b
Slide 12: Combination with LNTH Accelerates Strategic Priorities and Shareholder Value Creation
Lee lll 1 he e Combination with LNTH Accelerates Strategic Priorities and Shareholder © Value Creation . In addition to enhanced oversight, PGNX has continued to execute on its strategic objectives. 2019 Key Milestones = Progenics + \ppsamhsut. ¥ Broad clinical development experience indesigringand
Slide 13: Velan Continues to Make Overstretched Arguments to Seek Disproportional Change
Ne ————C Determined to Take Control, Velan Continues to Make Overstretched % / Arguments to Seek Disproportional Change As Gloss Lewis noted, Velan's “specious suggestion: \Velan’s Criticisms ‘are heavily weighted towards hindsight") PGNX Response i ‘Management was unable to successfully execute on
Slide 14: Part II: The LNTH / PGNX Combination Followed A Proper Process
Part Il: The LNTH / PGNX Combination Followed A | Jad Proper Process and Provides the Best Path Forward + y Offering Substantial and Sustainable Value to Vea X Shareholders @- te a ay Je Progenics ist oe roggnics wie Jam) a
Slide 15: PGNX Conducted a Proper Process for a Radiopharmaceutical Company
PGNX Conducted a Proper Process for a Radiopharmaceutical Company Y Lantheus expressed inbound interest in a combination. Progenics did not solicit interest from Lantheus before or after the arrival of Velan Good governance principles and fiduciary duties dictated Progenics evaluate the attractivene
Slide 16: Comprehensive Process to Maximize Shareholder Value
Nee ll th ce Comprehensive Process to Maximize Shareholder Value Ps Key Points Transaction Timeline Tan a9 antheusand rogencstthe PWeivarConfrcto daca wapto warKopa? ¥ Ongoing discussions began before any Feb."19 SVBLeerink contacts a Progenkcs Board member, at the direction of theLantheus Board, to
Slide 17: The Argument Against the Transaction Being Approved by Two Resigning Directors is a Red Herring
The Argument Against the Transaction Being Approved by Two Resigning Directors is a “Red Herring” ‘The transaction was under discussion before Velan’s initial engagement with PGNX Involvement Since Pratien Both Peter Crowley and Michael Kishbauch, as sitting Directors, were involved in deliberations
Slide 18: PGNX Equity Holders Will Participate in All Synergies and Future Upside
Unlike a Straight Sale, PGNX Equity Holders Will Participate in All Synergies and Potential Future Upside in the Combined Company PGNX equity holder ownership, giving equity holders a substantial Interest in the combined company 35% ‘At an announced premium to PGNX shareholders) ~21% ~$370m Pro form
Slide 19: The Transaction Provides Greater Value Opportunities Than Standalone
The Transaction Provides Greater Value Opportunities for PGNX Shareholders Than as a Standalone Company Progenics as a Standalone Company Value | Creation as a Combined Company Required costs incurred through the development of pipeline products and commercialization of AZEDRA Y Identified synergies
Slide 20: Velan's Areas of Concern Are Immediately Addressed Through the Transaction
Velan’s Areas of Concern are Immediately Addressed with a Higher Degree. of Certainty Through the Transaction with Lantheus ‘An experienced and successful CEO already n place who has a proven track record of cresting "273% in shareholder value”) 1 Placement of new top-tier CEOwithin60days ceo/ Een E
Slide 21: Velan's Areas of Concern Are Immediately Addressed (Cont.)
Velan’s Areas of Concern are Immediately Addressed with a Higher Degree. of Certainty Through the Transaction with Lantheus (Cont.) Where Velan’s Nominees Would Focust! PYLNDA readiness linieal aus + 1095 clinical tal desi = AZEDRA basket tial design = Cutunnecessary expenses, Financials & ae Financ
Slide 22: Announced Premium In Line with or Exceeds All-Stock Precedents
Announced Premium In Line with or Exceeds All-Stock Precedents, with * Potential for Future Stock Price Appreciation Remaining Intact e Oa so 30-Trading Day Share Price Premium Inline with Premium Paidin Comparable allsStock Precedents provides PGNX shareholders with an announced stock premium" in l
Slide 23: Transaction Driving Value for Shareholders
Transaction Driving Value for Shareholders ped Transaction Premium to: 75.0% ‘aa | | 2% 223% Eid ite max — — _— — (819) S2wkinadey igh —S2wWRinredoy tow 90-T0dingDoy_—=30TRading Dey 90 Trading Doys Por 30 Teding Doy Por Seven Trading Day Prior clos Stok Pree (10/05/2018) (09/20/2013) vwae war toAnmo
Slide 24: Part III: Shareholders Are Entitled to Full Disclosure on the Transaction
Part Ill: Shareholders Are Entitled to Full Disclosure on /. _§ the Transaction Before Making a Material Decision; ee Handing Control to Velan Now Could Lead to Chaos Veh and Value Destruction ee iM ind Fight and Follow”
Slide 25: Shareholders Should Have Complete Information About the Transaction
Ne ——— rf Shareholders Should Have Complete Information About the Transaction in Order to Make a Fully Informed Decision About the Composition of Progenics' Board Velan is wrongfully forcing shareholders into making a pivotal decision on the Company’s future before allowing shareholders to have all
Slide 26: Velan Shows Zero Commitment to Independently Evaluate the Transaction
Velan Shows Zero Commitment to Independently Evaluate the Transact ion | © \Velan has publicly and definitively rejected the transaction, prior to having full information, and criticized Lantheus’ operating and stock performance, showing zero commitment to independently evaluate the transaction ® On
Slide 27: A Successful Consent Solicitation by Velan Burdens Shareholders with Risk and Uncertainty
A Successful Consent Solicitation by Velan Burdens Shareholders with ¢ Risk and Uncertainty for the Future If Velan Succeeds in Their Consent Solicitation AND Rejects the Transaction... Unestablished Leadership % Current Board replaced with dissident nominees, unfamiliar with PGNKX, strong alignment
Slide 28: Velan's Proposed CEO, Mr. Mims, Is Not Qualified
—————— aaa eer e. Velan’s Board Member & Proposed CEO, Mr. Mims, is NOT QUALIFIED as * a Board Member, CEO or Acting CEO Candidate Not Qualified to bea CEO of ANY Public Company No Role in the Life Sciences Industry Since 2014 No Relevant Development or ‘Commercial Experience Commercial Track Record
Slide 29: Velan's Plan To Put $200 Million of Debt on Progenics Is Irresponsible
———————— SS a eer ’ Velan’s Plan To Put $200 Million of Debt on Progenics Is IRRESPONSIBLE *_ and Should Alarm Investors = Progenics would considera variety of financing alternatives in the absence of a transaction with Lantheus = However, $200 million of debt— “non-recourse” or otherwise — is an IR
Slide 30: For Velan, Board Control Outweighs Enhancing Value for All Shareholders
C «° For Velan, Board Control Outweighs Enhancing Value for ALL Shareholders e Velan’s actions show a lack of concern for other shareholders and a self-indulgent fight for Board control e Velan has proven they will consider nothing less than gaining full control of the Board + Velan quickly rejected
Slide 31: Hold Velan Accountable for Questionable Securities Trading, Governance and Ethical Practices
Ne ———C > e Shareholders Should Hold Velan Accountable for Questionable Securities Trading, Governance and Ethical Practices ‘September 15° ‘public keowiedge abou canketrer ite \Velan acquired “1 Smshares. eam cocee seers =a Scher | eee. an Sena JS, Why did Velanneverdlscoseltsoppastionto thedesl,pr
Slide 32: Velan Omitted PGNX's Latest Settlement Offer in Their ISS Presentation
In Their ISS Presentation, Velan Purposefully Omitted PGNX’s Latest Settlement Offer, Which Gave Velan Everything they Previously Demanded, Including CEO Resignation September 6,2019 © topics (Ceesaratesoyvean but noone wtotesuen ‘elon tseeteabyene Companytovesetecby elon andonesetesoy henewyrecensz
Slide 33: Part IV: A Board and Management Team Poised to Create Shareholder Value
Part IV: A Board and Management Team Poised to Create Shareholder Value é iy Progenics ia Be ni
Slide 34: Highly Experienced and Accomplished Board
—————— SSS een e -«° Highly Experienced and Accomplished Board.. Pro forma Lantheus + Progenics Board Well-balanced and highly qualified Board ¥ Lantheus’ Board will remain intact with the addition of Progenics’ independent Director, Bradley Campbell ¥ Director backgrounds are diverse and complement
Slide 35: That Delivers Shareholder Value
.. That Delivers Shareholder Value Mary Anne Heino wainois 2e70% v v v ‘an Markison sysr012 mars v v v v v Jamesclemmer 7phors 2as3% v v v v Samuelteno snow are v v v Jullenatugh anspor amas. v v v v ‘cary Pruden arenes o8 v v v Kenneth Puce anspois srs v v Dr. FredevckRobertson 2/8/2016 107798 v v
Slide 36: The Combined Company Is Led by an Experienced Leadership Team
The Combined Company Is Led by an Experienced Leadership Team John Bolla Chief Operations Officer ¥ Former VP. Supply Chain North America ot GSK, ‘amang other senior leadership roles ¥ 22 years of diverse supply chain, operations and ‘manufacturing experience in the pharma industry Mary Anne Heino P
Slide 37: Combined Board and Corporate Governance Highlights
Lee llUll— th e Combined Board and Corporate Governance Highlights Ps Board Highlights Corporate Governance Highlights Chairman: Independent Y Ability to call special meetings (50.1%) Board Size: 11 Y Abi ‘Average Director tenure: 3.1 years! SADR RE INSET OY EERSTE Pro forma Director stock ownership
Slide 38: A Combination with Lantheus Accelerates Strategic Priorities
Lee llUll— th e A Combination with Lantheus Accelerates Strategic Priorities Focused « on Creating Long-term Shareholder Value ¢ A highly complementary portfolio of ultrasound and radiopharmaceutical diagnostics and oncology therapeutics Diversified revenue streams, enhanced cashflow generation, eli
Slide 39: Shareholders Voted — PGNX Continues to Execute
Shareholders Voted — PGNX Continues to Execute Pe ‘The Progenics Board heard the call for chan, shareholder feedback at the Annual Meeting and has taken appropriate and responsive steps to address ‘The Lantheus transaction reflects the culmination of thoughtful discussion and analysis between Progen
Slide 40: Appendix
oa Appendix oe
Slide 41: PGNX Has Performed Largely In-Line with Peers
While the Oncology Biopharma Industry Has Experienced Challenges, PGNX Has Performed Largely In-Line with Peers... Weck shares (3%) ‘YoGNE shores (58) 1,, 3+, 5-Year TSR to 1-Day Prior to Lantheus Deal Announcement {sj lutssa vast conpasies that smProny Peers) Smal-Cop Onecogy Biopharma! mPGNX L J Y
Slide 42: Termination fee is in line with industry precedents
Termination fee is inline with industry precedents and not tied to Progenics shareholder approval Overview of Termination Fee + Company termination fee of $18,340,000is payable it: — Agreementis terminated due toi) a willful and material violation of the non-solicit or ii) Progenics’ board fails to
Slide 43: Increasing Value Through Synergy and Capital Enhancement
Increasing Value Through Synergy and Capital Enhancement Strategic Financial Near Term + Experienced management team with a “successful trackrecord of product ‘commercalization and operational execution + Effective Board oversight with strong ‘commercial, operational and financial expertise + Divers
Slide 44: Combination Drives Value Creation Across Multiple Fronts
Combination Drives Value Creation Across Multiple Fronts ¥_‘Transactionis atthe forefront of radiopharma’s trajectory ~ combining diagnostics and therapeutics to improve patient care Robust & Complementary Portfolio of Assets Complementary portfolio of ultrasound and radiopharmaceutical diagnostics
Slide 45: The Transaction Provides a Robust Pipeline with Clear Value Drivers
J The Transaction Provides a Robust Pipeline with Clear Value Drivers Rtitrrane-tervemneancenentan Wlilddiildddididddddildiddddda cece Beteorane-tanrerpeouctominen WM Ties iar £8 Petia! Peon maging ‘Rireberguone-Newoenscne Tas nPsre/ Ae Pondatons ‘erevt RetinalVin cco T Feny repeat eum teeay = anu I
Slide 46: Creating a Well-Balanced Portfolio of Diagnostics to Therapeutics
Creating a Well-Balanced Portfolio of Diagnostics to Therapeutics Precision Oncology A QUADRAMET <> AZEDRA a Xenon Xe 133 Gas: . ae eestor = aBS I [Galium erred S26rinecton (FOG 18) AZEORA RELISTOR QUADRAMET Automated Bone + Fist/onlyFOA. + Onlytretment * Injectable —_—Seanindex erwiry Radiopharmace
Slide 47: The Transaction Provides a Strong Financial Outlook
The Transaction Provides a Strong Financial Outlook Increased Gross + Gross margin improvement through enhanced revenue growth and realizable cost savings and effikencies Margins * Additional longer-term opportunities from diversified reverwe / product mix 7 * Complementary portfolio of assets and r
Slide 48: Highly Leveraged Biotech and Pharmaceutical Companies Have Been Punished by Investors
Highly Leveraged Biotech and Pharmaceutical Companies have been Punished by Investors Corn = teas) aisaPramacecn nos tars) Dpnartecnsagasconeatee bat fas) Kenan ‘00 ‘oe es esx) wo aes) oe eas) cus (sess) rene basrs) nee (55) neon ers) ous ares) mat (es33) ark rs)
Slide 49: Endocyte's Sale Price Is Not Comparable to Progenics
Endocyte’s Sale Price is Not Comparable to Progenics Given Differences in Probability of Success Driven by POC Data and Phase of Development Endocyte — Enterprise Value (TEV) Endocyies premium | taluwtlon drivenby, | SMincresad probability | siccessupportedby | InPhaseSregsnraont’ale! PSM, Tevots7i6
Slide 50: Blue Earth Transaction Value Is Not a Valid Comparison to Progenics' PyL
Blue Earth Transaction Value is Not a Valid Comparison to Progenics’ PyL ‘Negative, as funding required for ongoing Margin Profile Cash flow generating ‘cinical Gal Product ‘Axumin™ (flucielovine F18) PyL(#F-DCFPyL) | Indication PET imaging agent for prostate canc PET imaging agent for prostate canc
Slide 51: Velan Has Consistently Sought Disproportionate Influence
Velan Has Consistently Sought Disproportionate Influence - ‘rls, 2019 Api24,2019 Api, 2019 tune 13,2019 ——uly 1, 2019 __—September8, 2019 October8, 2019 —_Otaber 47, 2019 wo 219 Ache 7 “roto mers nating herethat os appeOstOROE WSs eraugrnann _ Welancaates OFFER ae reorntie forts ot sett “awe tore th
Slide 52: Timeline of Velan Knowledge and Latest Settlement Offer
Timeline of Velan Knowledge and Latest Settlement Offer Ps June21 ——_tantheus submits aprivate, nonbinding indication ofitresto acquire Prope. ‘August9 ——Propenesissues2020:9 earnings release ‘The velan Group issues pressrelesecritealt Progen. ‘August 12 Te closingprceofthe Prosencs hares declines 1
Slide 53: September–October Timeline
September 18 September 20 (October 17 October 18 TE buys total o 43,520 Progeicssharesats462 ‘elon demands PGR applnt Sof rector (2Velannominees and 3 mutually greed upon nominee), commie rolesfor new decor, standetilartnghoughthe 202086M, Boardchait ‘agreed upon by members ofthe econetutes Board, a
Slide 54: Shedding Light on Velan's False and Misleading Claims Surrounding Dr. Scheinberg
Ne ————C “EN Shedding Light on Velan’s False and Misleading Claims Surrounding Dr. Scheinberg’s “Conflicts” Velan’s Misleading Statements PGNX Board Truthful Response “Dr. Scheinberg was compensated...forhisservice asa Progenics x director. ‘Memorial Sloan Kettering ("MSK")has had recent issues rega
Slide 55: Velan's Potential Alarming Issues Are Unfounded and Inaccurate
Velan’s “Potential Alarming Issues” are Unfounded and Inaccurate Velan’s Misguided Attacks Direct Screenshots from Velan’s Investor Presenttion”™ "Not disclosing CPOC' import ban In August 2018 mere days before asing $75 milion na follow. on offering if known a the time) sna not dlosing IRs potentia
Slide 56: Peer Groups
—————— aaa eer @ «6° Peer Groups AGEN Agnus in. GMS 16M Biosciences, ine. AGEL Rees ne A510 AalosPharmaceuteas ne MEN Immunacen ne |8RY ray SloPharma in. UB poaptyBio, ne eT, KaryorharmTherapeties,in BCI Blocryst Pharmaceuticals, ne. sAQL — fOule, ne KURA Kura nesioy. ne 20S: BledeiverySelences inte
Progenics Pharmaceuticals — Proxy Contest (October 2019) on 6ix